Selexipag
-
Selexipag
structure -
-
CAS No:
475086-01-2
-
Formula:
C26H32N4O4S
-
Chemical Name:
Selexipag
-
Synonyms:
Selexipag;ACT-293987;NS-304(Selexipag);Selexipag API;2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylaMino]butoxy]-N-MethylsulfonylacetaMide;AcetaMide, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-Methylethyl)aMino]butoxy]-N- (Methylsulfonyl)-;Slipper;Selexipag intermediate 1
- Categories:
-
CAS No:
Description
Selexipag and its active metabolite, the corresponding carboxylic acid, are nonprostanoid prostaglandin I2 (PGI-2) receptor agonists. The N-methylsulfonamide within selexipag is hydrolyzed to the corresponding carboxylic acid in vivo by hepatic microsomes at a rate which provides a slow-release pharmacological effect. The compound was originally discovered by Nippon Shinyaki and later licensed to Actelion for development. The drug was approved in 2015 and first launched for the oral treatment of pulmonary arterial hypertension (PAH) in the U.S. in 2016 to delay disease progression and reduce the risk of hospitalization.
ChEBI: Selexipag is a member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the treatment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid). It has a role as an orphan drug, a prostacyclin receptor agonist, a platelet aggregation inhibitor, a vasodilator agent and a prodrug. It is a monocarboxylic acid amide, an ether, a member of pyrazines, an aromatic amine, a tertiary amino compound and a N-sulfonylcarboxamide. It is functionally related to an ACT-333679.
Selexipag Use and Manufacturing
Selexipag is an orally available, highly selective, long-acting prostacyclin (IP) receptor agonist prodrug. It is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans.
Drug Function and Efficacy
Selexipag is an oral prostacyclin receptor (IP receptor) agonist, which is structurally different from prostacyclin and is hydrolyzed by carboxylesterase 1 into an active metabolite, which is about 37 times more potent than selexipag. Selexipag and its active metabolites selectively act on IP receptors but have no effect on other prostaglandin receptors (EP, DP, FP, and TP).
Registered Holders
-
BIOPHORE INDIA PHARMACEUTICALS PVT LTD
Active
United States
-
MSN LABORATORIES PRIVATE LTD
Active
United States
-
APOTEX PHARMACHEM INDIA PVT LTD
Active
United States
Recommended Suppliers of Selexipag
-
CN
5 YRS
Business licensedTrader Supplier of Pharmaceuticals,Peptide,Cosmetics,Nutritional SupplementsInquiryCAS No.: 475086-01-2Grade: Pharmaceutical GradeContent: 99.5% -
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
CN
6 YRS
Business licensed Certified factoryManufactory Supplier of fine chemicals,peg derivatives,pharma intermediates -
CN
2 YRS
Business licensedTrader Supplier of Glutathione,Arbutin,Kojic acid,Polycaprolactone,Hydroxyapatite,EMT,Phase Change Microcapsule,AVC powder,PLLA,PLGA,API -
CN
4 YRS
Business licensed Certified factoryManufactory Supplier of Betahistine Mesylate,Azilsartan Medoxomil Potassium,Pimavanserin Tartrate,Iguratimod
Learn More Other Chemicals
-
3-(3-CHLOROPROPYLCARBAMOYL)BENZENEBORONIC ACID
874288-10-5
-
3-Pyridinecarboxylic acid, 2,6-dichloro-, ethyl ester
58584-86-4
-
(+)-Mesembrenone
468-54-2
-
1,5-Methano-1H-3-benzazepine, 2,3,4,5-tetrahydro-, hydrochloride (1:1) Formula
230615-52-8
-
(4-acetyloxyphenyl)-(4-acetyloxyphenyl)imino-oxidoazanium Formula
79030-44-7
-
1-(4-Methoxy-phenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde Formula
347331-30-0
-
2,2'-DIAMINODIPHENYL SULFIDE Structure
5873-51-8
-
AC-ARG-PHE-MET-TRP-MET-ARG-NH2 Structure
152274-65-2
-
What is 1,1-Dimethylethyl 2-bromo-2-methylpropanoate
23877-12-5
-
What is 1,3-Dichloro-2,4-difluorobenzene
36556-37-3